// App-Quantinova.ai

P315 : Systemic and tissue modulation of IL-23 pathway biomarkers in a Phase 2 study of risankizumab in patients with Crohn’s disease

Researchers

Presenter

  • A Salas

Principal Investigators

  • K M Grebe

  • N Powell

  • J Pans

  • J W Davis

  • F Hong

  • Y Pang

  • A A Suleiman

  • K Wallace

  • B G Feagan

Medical Centers

  • Hospital Clinic Barcelona, Barcelona, Spain

  • AbbVie Inc., Worcester MA, USA

  • Guys and St ThomasHospital, London, UK

  • AbbVie, Inc., North Chicago, IL

  • AbbVie Inc., Ludwigshafen am Rhein, Germany

  • University of Western Ontario, London, ON, Canada

Locations

  • Spain

  • United States

  • United Kingdom

  • Germany

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • Crohn's disease

Biomarkers

  • Interleukin-22

  • Interleukin-23

Drug/Treatment

  • Risankizumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • II

Study Id's

  • NCT02031276

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved